Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01823016 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
NCT01823016: Completed Phase 2 study, sponsored by Janssen Research & Development.
NCT01823016 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 166 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01823016, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-38518168 compared with placebo in participants with persistent asthma that is inadequately controlled despite current treatment.
Primary Outcome
Expressed as percent of predicted value.
Interventions
- DRUG Placebo
- DRUG JNJ-38518168
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2013-09 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
What the finished NCT01823016 record still lists
NCT01823016 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01823016 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01823016 about?
NCT01823016 is a clinical study titled "A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma". The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-38518168 compared with placebo in participants with persistent asthma that is inadequately controlled despite current treatment.
What is the current status of trial NCT01823016?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2013-09. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01823016?
The interventions under investigation include: Placebo (DRUG), JNJ-38518168 (DRUG).
Who is sponsoring clinical trial NCT01823016?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01823016's enrollment target sits among peer trials
166 406th of 2000 higher than 1,591 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia